Last reviewed · How we verify

NCT04406805: TASTE

TMAO in Patients With Severe Aortic Stenosis

Status unknown Last updated 5 June 2020
What this trial tests

trial testing Measurement of plasma and urine trimethylamine-N-oxide concentration in Aortic Stenosis in 70 participants. Status unknown.

Timeline
15 January 2019
Primary endpoint
15 February 2022
15 February 2023

Quick facts

Lead sponsorMedical University of Warsaw
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment70
Start date15 January 2019
Primary completion15 February 2022
Estimated completion15 February 2023
Sites1 location across Poland

Drugs / interventions tested

Conditions studied

Sponsor

Medical University of Warsaw

Who can join

Adults 18 to 99, any sex, with Aortic Stenosis or Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Trimethylamine N-oxide (TMAO) has recently gained increasing scientific interest in the field of cardiovascular disease, including its role in cell protection against osmotic and hydrostatic stress. Aortic stenosis (AS) is the most common valvular heart disease, affecting about 7.6 million people over 75 years of age in North America and Europe alone. We hypothesized that TMAO plays a role in protection of the cardiomyocytes against pressure overload in patients with AS. The primary aim of this study is to assess the correlation between the serum and urine TMAO concentration, and (i) echocardiographic, (ii) biochemical and (iii) histopathological parameters of heart failure in patients with severe AS. The secondary aim of this study is to evaluate a correlation between the baseline TMAO concentrations and the post-treatment clinical status, as well as the post-treatment echocardiographic and biochemical parameters.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Trimethylamine-N-oxide (TMAO) versus echocardiographic, biochemical and histopathological indices of heart failure in patients with severe aortic stenosis: Rationale and design of the prospective, observational TASTE study.
    Gąsecka A, Rzepa Ł, Konwerski M, Zawadzka M, et al · · 2022 · cited 1× · PMID 35470417 · DOI 10.5603/cj.a2022.0023

Verify or expand the search:

Other recruiting trials for Aortic Stenosis

Currently open trials in the same condition.

Other Medical University of Warsaw trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04406805.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing